# SASCIA (NCT04595565)

> Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04595565
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: GBG Forschungs GmbH
- Conditions: HER2-negative Breast Cancer; Triple Negative Breast Cancer
- Interventions: Capecitabine; Carboplatin; Cisplatin; Sacituzumab govitecan
- Enrollment: 1332
- Primary outcome: Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physician's choice.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 8
- YouTube: 5
- X threads: 1
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=sascia-nct04595565

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04595565", "email": "<work email>"}; the inbox owner confirms by the emailed link.